Roche and Affymetrix get US nod for first-of-its-kind DNA test
This article was originally published in Clinica
The US FDA has cleared, for the first time, a DNA microarray test that could help doctors determine the success of medications for a variety of conditions, including cardiac disease, psychiatric disease and cancer. The AmpliChip Cytochrome P450 genotyping test, made by Roche Molecular Systems, of Pleasanton, California was cleared for use with Affymetrix' GeneChip Microarray system. According to the agency, the product could pave the way for the development of similar tests.
You may also be interested in...
Draft policy moots crowdfunding for high-cost rare diseases alongside financial support for those "amenable to one-time treatment" but falls way short of some patient groups' expectations.
India’s Hilleman Laboratories says it’s aiming to develop an affordable vaccine that will target pregnant women in low- and middle-income countries to prevent Group B Streptococcus, a potentially fatal infection passed to babies during childbirth.
Chi-Med’s surufatinib has come up trumps in a second trial in neuroendocrine tumors, after the monitoring committee recommended an early halt following achievement of its PFS target in the pancreatic setting.